Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab and Axitinib in localized mucosal melanoma
NCT04180995Phase 2Unknown
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Aug 2019
- Primary completion
- Jul 2022
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in mucosal melanoma (MM), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Pathological Response (pCR+pPR) Rate at 8 weeks. Status: unknown.
02
Drugs
toripalimab
03
Conditions
mucosal melanoma (MM)
Beyond the preview
Go deeper on NCT04180995.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04180995.